Dr. Leidner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4805 NE Glisan St
Ste 6N40
Portland, OR 97213Phone+1 503-215-5696Fax+1 216-983-0596
Education & Training
Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Virginia Mason Franciscan HealthResidency, Internal Medicine, 2003 - 2006
Maimonides Medical CenterResidency, Internal Medicine, 2001 - 2002
Tel Aviv University SacklerClass of 1999
Certifications & Licensure
WA State Medical License 2005 - 2026
OR State Medical License 2012 - 2025
OH State Medical License 2006 - 2009- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma Start of enrollment: 2005 Oct 01
- Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer Start of enrollment: 2014 Apr 01
Publications & Presentations
PubMed
- Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial.Juanita Lopez, Thomas Powles, Fadi Braiteh, Lillian L Siu, Patricia LoRusso
Nature Medicine. 2025-01-01 - Widespread Adoption of Precision Anticancer Therapies After Implementation of Pathologist-Directed Comprehensive Genomic Profiling Across a Large US Health System.Alexa K Dowdell, Ryan C Meng, Ann Vita, Bela Bapat, Douglas Hanes
JCO Oncology Practice. 2024-11-01 - Palbociclib in Patients With Head and Neck Cancer and Other Tumors WithAlterations: Results From the Targeted Agent and Profiling Utilization Registry Study.Francis P Worden, Evan Pisick, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer
JCO Precision Oncology. 2024-10-01
Press Mentions
Novel Genetic Experiment Narrows down Hard-to-Treat CancerJune 27th, 2022- Deadly Cancer Quickly Shrinks by 50% with ‘One-and-Done’ Therapy: StudyJune 3rd, 2022
- ‘One-and-Done’ Therapy Shrinks Deadly Cancer 50% Faster: StudyJune 3rd, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
